BioLingus AG - Product Pipeline Review

Global Markets Direct’s, ‘BioLingus AG - Product Pipeline Review - 2016’, provides an overview of the BioLingus AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG

The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses BioLingus AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features BioLingus AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate BioLingus AG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for BioLingus AG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding BioLingus AG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

BioLingus AG ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

BioLingus AG Snapshot 6

BioLingus AG Overview 6

Key Facts 6

BioLingus AG - Research and Development Overview 7

Key Therapeutic Areas 7

BioLingus AG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

BioLingus AG - Pipeline Products Glance 11

BioLingus AG - Early Stage Pipeline Products 11

Preclinical Products/Combination Treatment Modalities 11

Discovery Products/Combination Treatment Modalities 12

BioLingus AG - Unknown Stage Pipeline Products 13

Unknown Products/Combination Treatment Modalities 13

BioLingus AG - Drug Profiles 14

aldesleukin - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

Cellular Immunotherapy to Target Survivin for Oncology - Drug Profile 15

Product Description 15

Mechanism Of Action 15

R&D Progress 15

exenatide biobetter - Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

interferon alfa biobetter - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

interferon gamma - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

interleukin 2 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Synthetic Peptide to Agonize GLP-1 for Type 2 Diabetes - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Synthetic Peptide to Inhibit TNF-Alpha for Rheumatoid Arthritis - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

BioLingus AG - Pipeline Analysis 24

BioLingus AG - Pipeline Products by Target 24

BioLingus AG - Pipeline Products by Route of Administration 25

BioLingus AG - Pipeline Products by Molecule Type 26

BioLingus AG - Pipeline Products by Mechanism of Action 27

BioLingus AG - Locations And Subsidiaries 28

Head Office 28

Appendix 29

Methodology 29

Coverage 29

Secondary Research 29

Primary Research 29

Expert Panel Validation 29

Contact Us 29

Disclaimer 30

List of Tables

List of Tables

BioLingus AG, Key Facts 6

BioLingus AG - Pipeline by Indication, 2016 8

BioLingus AG - Pipeline by Stage of Development, 2016 ...

List of Tables

BioLingus AG, Key Facts 6

BioLingus AG - Pipeline by Indication, 2016 8

BioLingus AG - Pipeline by Stage of Development, 2016 9

BioLingus AG - Monotherapy Products in Pipeline, 2016 10

BioLingus AG - Preclinical, 2016 11

BioLingus AG - Discovery, 2016 12

BioLingus AG - Unknown, 2016 13

BioLingus AG - Pipeline by Target, 2016 24

BioLingus AG - Pipeline by Route of Administration, 2016 25

BioLingus AG - Pipeline by Molecule Type, 2016 26

BioLingus AG - Pipeline Products by Mechanism of Action, 2016 27

List of Figures

List of Figures

BioLingus AG - Pipeline by Top 10 Indication, 2016 8

BioLingus AG - Pipeline by Stage of Development, 2016 9

BioLingus AG ...

List of Figures

BioLingus AG - Pipeline by Top 10 Indication, 2016 8

BioLingus AG - Pipeline by Stage of Development, 2016 9

BioLingus AG - Monotherapy Products in Pipeline, 2016 10

BioLingus AG - Pipeline Target, 2016 24

BioLingus AG - Pipeline by Route of Administration, 2016 25

BioLingus AG - Pipeline by Molecule Type, 2016 26

BioLingus AG - Pipeline Products by Mechanism of Action, 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports